Integrin Alpha-2 Binding Agents Inhibit Cancer Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effectiveness in treating and preventing cancer cell proliferation, particularly in relation to integrin alpha-2, which is implicated in various cancers and metastasis.
Innovation Solution
Development of integrin alpha-2 binding agents, such as antibodies or antibody fragments, that cross-block the binding of specific antibodies to integrin alpha-2, inhibiting cancer cell proliferation and modulating tumor growth by administering these agents to effectively target cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cancer cell proliferation, then treatment is provided, but they lack effectiveness in treating and preventing cancer cell proliferation
Solution Approach 1:
The patent uses integrin alpha-2 binding agents as intermediary molecules that specifically bind to integrin alpha-2 receptors on cancer cells, blocking their interaction with extracellular matrix components. This mediator approach prevents cancer cell proliferation by interfering with the cell-matrix signaling pathway without directly damaging the cell, thereby improving therapeutic effectiveness while reducing harmful side effects
Solution Approach 2:
The patent employs monoclonal antibodies with specific binding affinities to integrin alpha-2, changing the binding parameter of the therapeutic agent to target the specific integrin receptor. By selecting antibodies with optimized binding characteristics (such as those that cross-block binding), the therapy achieves higher effectiveness in preventing cancer cell proliferation compared to non-specific therapies
2Reliability
If integrin alpha-2 binding agents are developed to cross-block antibody binding, then cancer cell proliferation is inhibited, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts the specific binding function from complex antibody molecules by identifying and utilizing the complementarity-determining regions (CDRs) that are responsible for integrin alpha-2 binding. By focusing on these essential binding elements, the therapy achieves cancer cell proliferation inhibition through a more targeted and less complex mechanism compared to using entire antibody molecules or non-specific agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The integrin alpha-2 binding agents inhibit cancer cell proliferation in three-dimensional cell cultures and modulate tumor growth, offering a therapeutic approach to reduce cancer cell proliferation and angiogenesis, as well as treating fibrotic disorders.
Implementation Method 1
integrin alpha-2 binding agents and uses thereof to inhibit cancer cell proliferation... integrin alpha-2 binding agent that cross-blocks the binding of at least one of antibodies 770.8, 778.17, and 774.3 to integrin alpha-2
Data Source
AI summary
The invention provides an integrin alpha-2 binding agent and methods of using an integrin alpha-2 binding agent to, e.g., inhibit proliferation of cancer cells, modulate tumor growth in a subject, inhibiting angiogenesis, or treating a fibrotic disorder. The invention further provides a method of producing an antibody, the method comprising propagating cancer cells in a 3-dimensional matrix; immunizing a mammal with the propagated cancer cells; and isolating an antibody from the immunized mammal. A method of identifying an agent that inhibits cancer cell proliferation also is provided.